We are live on ! Find out more
MKA

M. Kulyk & Associates Portfolio holdings

AUM $536M
1-Year Est. Return 18.28%
This Fund
S&P 500
This Quarter Est. Return
+10.9%
1 Year Est. Return
+18.28%
3 Year Est. Return
+52.28%
5 Year Est. Return
+66.13%
10 Year Est. Return
AUM
$429M
AUM Growth
+$69.3M
Cap. Flow
+$30.1M
Cap. Flow %
7.02%
Top 10 Hldgs %
40.17%
Holding
113
New
18
Increased
49
Reduced
28
Closed
5

Top Sells

Rank Stock Value
1
WSM icon
Williams-Sonoma
WSM
+$596K
2
SCHD icon
Schwab US Dividend Equity ETF
SCHD
+$514K
3
TSLA icon
Tesla
TSLA
+$394K
4
AMGN icon
Amgen
AMGN
+$257K
5
PFE icon
Pfizer
PFE
+$242K

Sector Composition

Rank Sector Weight
1 Technology 22.04%
2 Financials 11.68%
3 Consumer Discretionary 11.31%
4 Healthcare 9.87%
5 Consumer Staples 6.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AMGN icon
26
Amgen
AMGN
$210B
$6.45M 1.5%
22,394
-944
-4% -$257K
ZTS icon
27
Zoetis
ZTS
$31.9B
$6.38M 1.49%
32,321
+1,229
+4% +$218K
SWKS icon
28
Skyworks Solutions
SWKS
$10.1B
$6.38M 1.49%
56,734
+4,149
+8% +$406K
PG icon
29
Procter & Gamble
PG
$345B
$6.37M 1.48%
43,483
+512
+1% +$75.8K
INTU icon
30
Intuit
INTU
$88.5B
$6.23M 1.45%
9,964
+62
+0.6% +$34.2K
CRM icon
31
Salesforce
CRM
$156B
$5.79M 1.35%
22,009
-36
-0.2% -$8.15K
JCI icon
32
Johnson Controls International
JCI
$93.1B
$5.77M 1.34%
100,053
+7,108
+8% +$373K
WSM icon
33
Williams-Sonoma
WSM
$29.3B
$5.25M 1.22%
51,988
-6,880
-12% -$596K
TGT icon
34
Target
TGT
$67.3B
$5.14M 1.2%
36,086
+3,527
+11% +$431K
XYL icon
35
Xylem
XYL
$28.5B
$5.09M 1.18%
44,478
+3,312
+8% +$331K
BAX icon
36
Baxter International
BAX
$14.7B
$4.3M 1%
111,134
+18,583
+20% +$657K
GIS icon
37
General Mills
GIS
$19.3B
$4.3M 1%
65,944
+2,745
+4% +$177K
LH icon
38
Labcorp
LH
$25.3B
$4.26M 0.99%
18,762
+1,040
+6% +$218K
BDX icon
39
Becton Dickinson
BDX
$46.9B
$4.2M 0.98%
17,219
+579
+3% +$143K
ARE icon
40
Alexandria Real Estate Equities
ARE
$8.52B
$4.13M 0.96%
32,583
+660
+2% +$71K
CGNX icon
41
Cognex
CGNX
$11.9B
$4.01M 0.93%
96,136
+18,555
+24% +$713K
EXC icon
42
Exelon
EXC
$47.2B
$3.69M 0.86%
102,757
+39
+0% +$1.5K
VFC icon
43
VF Corp
VFC
$5.99B
$3.67M 0.85%
195,232
+23,762
+14% +$408K
AXP icon
44
American Express
AXP
$234B
$3.4M 0.79%
18,170
-900
-5% -$145K
CLX icon
45
Clorox
CLX
$12.7B
$3.39M 0.79%
23,752
+607
+3% +$80.9K
DEO icon
46
Diageo
DEO
$48.8B
$3.12M 0.73%
21,392
+130
+0.6% +$19.2K
GLW icon
47
Corning
GLW
$137B
$3.04M 0.71%
99,802
+11,127
+13% +$318K
NEE icon
48
NextEra Energy
NEE
$182B
$2.89M 0.67%
47,645
+6,785
+17% +$387K
UL icon
49
Unilever
UL
$138B
$2.84M 0.66%
52,009
+2,900
+6% +$156K
STLD icon
50
Steel Dynamics
STLD
$38B
$2.42M 0.56%
20,491
-685
-3% -$76.3K

Similar funds

M. Kulyk & Associates's Q4 2023 Portfolio in Review

As of Q4 2023, M. Kulyk & Associates held 113 positions worth $429M, up 19% from $360M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

M. Kulyk & Associates deployed $30.1M of net new capital in Q4 2023, opening 18 new positions and adding to 49 existing holdings. Its largest new stake was iShares 0-3 Month Treasury Bond ETF: 86,325 shares worth $8.66M.

By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 22% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was Williams-Sonoma, an estimated $596K trimmed.

  • M. Kulyk & Associates's largest Q4 2023 buy was iShares 0-3 Month Treasury Bond ETF: 86,325 shares worth $8.66M.
  • M. Kulyk & Associates added most to iShares 0-1 Year Treasury Bond ETF in Q4 2023, an estimated $3.14M increase.
  • M. Kulyk & Associates's biggest Q4 2023 reduction was Williams-Sonoma, cutting an estimated $596K.
  • M. Kulyk & Associates fully exited Schwab US Dividend Equity ETF in Q4 2023, selling an estimated $514K.
  • M. Kulyk & Associates's ten largest holdings make up 40% of its $429M portfolio in Q4 2023.
  • M. Kulyk & Associates opened 18 new positions and closed 5 in Q4 2023.
  • M. Kulyk & Associates's portfolio value rose 19% quarter-over-quarter to $429M.

Based on M. Kulyk & Associates's 13F filing for Q4 2023, filed 8 Feb 2024.